key: cord-0694868-2ky7qdn0
authors: Perez-Zsolt, Daniel; Muñoz-Basagoiti, Jordana; Rodon, Jordi; Elousa, Marc; Raïch-Regué, Dàlia; Risco, Cristina; Sachse, Martin; Pino, Maria; Gumber, Sanjeev; Paiardini, Mirko; Chojnacki, Jakub; Erkizia, Itziar; Muñiz, Xabier; Ballana, Ester; Riveira-Muñoz, Eva; Noguera, Marc; Paredes, Roger; Trinité, Benjamin; Tarrés-Freixas, Ferran; Blanco, Ignacio; Guallar, Victor; Carrillo, Jorge; Blanco, Julià; Telenti, Amalio; Heyn, Holger; Segalés, Joaquim; Clotet, Bonaventura; Martinez-Picado, Javier; Vergara-Alert, Júlia; Izquierdo-Useros, Nuria
title: Siglec-1 on dendritic cells mediates SARS-CoV-2 trans-infection of target cells while on macrophages triggers proinflammatory responses
date: 2021-05-14
journal: bioRxiv
DOI: 10.1101/2021.05.11.443572
sha: f7a3915833a96e7b59836f572031fb81f481b100
doc_id: 694868
cord_uid: 2ky7qdn0

COVID-19 pandemic is not yet under control by vaccination, and effective antivirals are critical for preparedness. Here we report that macrophages and dendritic cells, key antigen presenting myeloid cells (APCs), are largely resistant to SARS-CoV-2 infection. APCs effectively captured viruses within cellular compartments that lead to antigen degradation. Macrophages sense SARS-CoV-2 and released higher levels of cytokines, including those related to cytokine storm in severe COVID-19. The sialic acid-binding Ig-like lectin 1 (Siglec-1/CD169) present on APCs, which interacts with sialylated gangliosides on membranes of retroviruses or filoviruses, also binds SARS-CoV-2 via GM1. Blockage of Siglec-1 receptors by monoclonal antibodies reduces SARS-CoV-2 uptake and transfer to susceptible target cells. APCs expressing Siglec-1 and carrying SARS-CoV-2 are found in pulmonary tissues of non-human primates. Single cell analysis reveals the in vivo induction of cytokines in those macrophages. Targeting Siglec-1 could offer cross-protection against SARS-CoV-2 and other enveloped viruses that exploit APCs for viral dissemination, including those yet to come in future outbreaks.

Despite the efficacy and progress of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), future viral variants and other coronaviruses with similar outbreak potential might overcome these strategies and will require treatments yet to be developed. Since global immunization campaigns will likely require years to cover all the population worldwide, there is an urgent need to implement effective therapeutic treatments to reduce the mortality associated with severe coronavirus infectious disease 2019 . The respiratory illness caused by SARS-CoV-2 leads to hospitalization in 10-30% of the infected individuals and, eventually, the admission into the intensive care unit (CDC Weekly, 2020; European Center for Disease Prevention and Control, 2020). Severe COVID-19 is associated with pneumonia, dyspnea, hypoxemia and lymphopenia, and can rapidly progress to respiratory failure (Berlin et al., 2020) . Acute respiratory distress syndrome (ARDS) is also a common complication and is associated with a disproportionate inflammatory response to SARS-CoV-2, characterized by a cytokine storm-like syndrome (Hadjadj et al., 2020; Huang et al., 2020; Mehta et al., 2020; Valle, 2020) . Of note, mortality rate in COVID-19-associated ARDS is 45%, and the incidence of ARDS among non-survivors of COVID-19 is 90% (Tzotzos et al., 2020) .

Earlier studies have highlighted the paramount role of myeloid antigen-presenting cells (APCs), such as macrophages and dendritic cells (DCs), in mediating an antiviral inflammatory response, which is exacerbated in severe COVID-19 cases (Bain et al., 2021; Merad and Martin, 2020) . A critical role of lung macrophages in inducing the inflammation associated with the pathologic sequelae of SARS-CoV-2 infection has been confirmed also in nonhuman primates (NHP) (Hoang et al., 2021) . Yet, whether these cells effectively trap and process SARS-CoV-2, and if their viral detection results in the secretion of inflammatory cytokines need further investigation. Myeloid APCs might contribute to viral pathogenesis if they are susceptible to infection, or able to capture and transfer infectious viruses to bystander target cells, thereby favoring viral spread to other tissues (Geijtenbeek et al., 2000; Moller-Tank and Maury, 2015; Sewald et al., 2016) . Indeed, viral dissemination mediated by APCs is a common pathway coopted by different types of viruses to evade immunity, as it is the case of the human immunodeficiency virus type 1 (HIV-1), which is effectively transferred to target cells 4 via a mechanism known as trans-infection (Cameron et al., 1992; Geijtenbeek et al., 2000) . For other viruses, such as Ebola virus, productive infection of APCs is critical in determining host susceptibility and viral dissemination to distant tissues (Geisbert et al., 2003; Martines et al., 2015) .

Early interactions between viruses and macrophages or DCs are critical to either trigger immune responses or favor viral dissemination. For SARS-CoV-2, the outcome of such interactions has not been fully explored, although it might impact the progression of the COVID-19 severity. Thus, elucidating the initial steps of viral interaction with myeloid APCs is essential for the design of new therapies to increase protection of exposed individuals. Several lectin receptors are critical for initial viral recognition on APCs. Ctype lectins such as DC-specific intercellular adhesion molecule-3-Grabbing nonintegrin (DC-SIGN) mediate the attachment of several viruses such as HIV-1 or Ebola virus via viral glycoprotein recognition (Alvarez et al., 2002; Geijtenbeek et al., 2000; Lin et al., 2003; Simmons et al., 2003) , being also the case for SARS-CoV-2 (Thépaut et al., 2020) . The sialic acid-binding lectin Siglec-1 is an interferon inducible receptor expressed on activated myeloid cells (Hartnell et al., 2001; Pino et al., 2015; Puryear et al., 2013 ) whose expression is up-regulated on APCs in SARS-CoV-2 infected individuals (Bedin et al., 2020) . Siglec-1 is implicated in the binding of HIV-1 and Ebola virus via the recognition of sialylated ligands exposed on the lipid membranes of these viruses. The V-set domain of Siglec-1 interacts with sialyllactose on viral membrane gangliosides (Izquierdo-Useros et al., 2012a , 2012b Puryear et al., 2012 Puryear et al., , 2013 , which HIV-1, Ebola virus and other enveloped viruses incorporate during the budding from the membranes of infected cells (Bavari et al., 2002; Chan et al., 2008; Feizpour et al., 2015; Izquierdo-Useros et al., 2012a; Kalvodova et al., 2009 ). However, a general role for Siglec-1 in facilitating SARS-CoV-2 uptake and trans-infection to pulmonary target cells such as pneumocytes or respiratory ciliated cells remains largely unexplored, despite being one of the lectins that are highly expressed on pulmonary macrophages.

Here we show that, although being largely resistant to SARS-CoV-2 infection, myeloid cells effectively capture and trap incoming viruses in internal compartments connected with the plasma membrane, eventually leading to viral degradation overtime. Among the myeloid cells tested, macrophages released higher amounts of inflammatory cytokines upon viral sensing, including those involved in the cytokine storm associated 5 to ARDS (Hadjadj et al., 2020; Huang et al., 2020; Mehta et al., 2020; Valle, 2020) .

Finally, we show that Siglec-1 mediates SARS-CoV-2 recognition of different viral variants of concern via interaction with sialylated ligands, such as the ganglioside GM1 identified on SARS-CoV-2 membrane. Immunohistochemistry and single cell RNA analyses of pulmonary tissues of SARS-CoV-2 infected NHP corroborated, directly in vivo, the presence of Siglec-1 on myeloid cells containing viruses. Siglec-1 capacity to bind SARS-CoV-2 was more relevant than other well-known attachment receptors such as DC-SIGN, and more effective at mediating transfer of viruses to susceptible target cells via trans-infection. Since anti-Siglec-1 monoclonal antibodies (mAbs) blocked SARS-CoV-2 trans-infection, targeting Siglec-1 could offer cross-protection against different SARS-CoV-2 variants and other enveloped viruses that exploit APCs for viral dissemination.

Preliminary reports indicate that myeloid cells such as monocyte-derived macrophages and DCs are highly resistant to coronavirus infection (Dalskov et al., 2020; Tynell et al., 2016; Yilla et al., 2005) . In line with these findings, we observed a reduction above 50% in the viability of susceptible Vero E6 cells 3 days post SARS-CoV-2 infection, that was not observed for monocyte-derived myeloid cells ( Figure 1A) . Of note, upon SARS-CoV-2 invasion, myeloid cells responded to activating signals that initiate antiviral responses, such as the release of type I interferon-α (IFN-α), or to the presence of bacterial lipopolysaccharide (LPS), which are increased throughout the course of SARS-CoV-2 infection (Giron, 2021 ). Thus, we tested the fusion capacity of SARS-CoV-2 spike on myeloid cells activated or not in the presence of IFN-α. Reporter pseudoviral vectors expressing VSV glycoprotein effectively fused with both macrophages and DCs, although it decreased on IFN-α treated myeloid cells ( Figure   1B ). However, fusion was always negligeable when pseudoviruses were pseudotyped with SARS-CoV-2 spike. Of note, both pseudoviruses effectively fused with HEK-293T cells expressing ACE2. For SARS-CoV-2 spike pseudovirus this was specifically blocked by a human ACE2-Fc fusion protein, which was not active on myeloid cells ( Figure 1B) .

Next, we compared the capacity of myeloid cells activated or not in the presence of IFN-α to capture SARS-CoV-2 by an ELISA measuring the amount of cell-associated virus. We followed the fate of these viruses for two days, assessing the amount of cellassociated virus captured overtime while measuring the amount of virus remaining in the supernatant ( Figure 1C) . Maximal viral uptake on cells was detected 4 h post viral addition, and decreased overtime for activated and non-activated myeloid cells, indicating that APCs were effectively processing captured viruses, since SARS-CoV-2 detected in the supernatant also diminished over time ( Figure 1C ). After extensive cellular washing, degradation of viruses trapped for 4 h was also assessed on macrophages and DCs previously activated or not with IFNα ( Figure 1D ). Cellassociated viruses detected at 4 h were quickly degraded after 24 h of culture, confirming that APCs were effectively processing captured viruses ( Figure 1D ). This 7 was not due to the release of bound viruses to the supernatant, where no SARS-CoV-2 accumulation could be detected over time ( Figure 1D) . Moreover, the absence of viral secretion to the media confirmed the inefficient viral replication of SARS-CoV-2 in myeloid cells regardless of their activation status ( Figure 1D ). In agreement with these results, electron microscopy micrographs of myeloid cells showed SARS-CoV-2 particles associated with sack-like structures resembling viral containing compartments (VCC) on APCs (Figure 1E) , as already described for other viruses (Perez-Zsolt et al., 2019; Yu et al., 2008) . On DCs ( Figure 1E , first two images on the top) we found extracellular viruses attached to invaginations of the plasma membrane or VCCs that appear also as vacuoles. These structures were however connected to the plasma membrane. In addition, we found viruses on large membranous compartments resembling degradative structures, where damaged viral particles were observed ( Figure 1E , last image on the top). On Macrophages ( Figure 1E , first image on the bottom) we also found extracellular viruses attached to the plasma membrane, but also on vesicles filled with material that marks them as endocytic structures ( Figure 1E , last two images on the bottom). Hence, viruses were effectively captured by APCs, especially upon cellular activation, that were in any case effectively processed by all APCs.

We then sought to see if SARS-CoV-2 captured and processed by non-activated monocyte-derived myeloid cells could induce cytokine release upon initial viral sensing using Luminex. The fold change in the secretion of cytokines and chemokines by myeloid cells exposed to SARS-CoV-2 as compared to those left untreated was measured over time. One day after SARS-CoV-2 exposure, macrophages released increased levels of IL-6 ( Figure 2A ) and cytokine secretion was maintained at 48 h. A much lower viral-induced release of IL-6 was observed for DCs at 24 h and was lost overtime (Figure 2A) . Similar dynamics were observed for tumor necrosis factor-α (TNF-α) and macrophage inflammatory protein-1α (MIP-1α) on DCs. In macrophages, TNF-α was also induced 2-fold upon SARS-CoV-2 exposure 4 h and 24 h after viral exposition, and above six-fold at 48 h (Figure 2A) . MIP-1α was up-regulated 4 h after viral exposure in macrophages, but the release of this chemokine decreased to basal levels at 48 h (Figure 2A) . Interferon-γ inducible protein 10 (IP-10) was induced by 8 SARS-CoV-2 over time in macrophages, and in this particular case, the induction was higher for DCs than for macrophages (Figure 2A) . These data indicate that macrophages sensed and responded to SARS-CoV-2 more effectively than DCs, although both cellular types efficiently engulfed and degraded these viruses.

We therefore focused on macrophages, and quantified the concentration of cytokines released one day after viral exposure, and the fold change in cytokine secretion as compared to mock-treated cells ( Figure 2B ). Among the viral-induced cytokines, the most abundantly secreted proteins increased after macrophage viral sensing were IP-10, followed by IL-6, MIP-1 α , IFN-2α, TNF-α, and then by IL-4 and IFNγ ( Figure 2B ).

Of those, IFN-2α, IL-6, and MIP-1α increased more than 20 times as compared to untreated macrophages ( Figure 2C ). MCP-1, IL-2 and IL-7 secretion were however not increased by SARS-CoV-2 exposure ( Figure 2C ). Thus, among myeloid cells, macrophages secreted higher levels of cytokines upon SARS-CoV-2 recognition compared to DCs. While released interferons may have antiviral properties, cytokines such as IL-6, MIP-1α or TNF-α are involved in the disproportionate inflammatory storm-like response against SARS-CoV-2 that is associated to the ARDS complication of COVID-19 (Hadjadj et al., 2020; Huang et al., 2020; Mehta et al., 2020; Valle, 2020) . 

Siglec-1 is upregulated on myeloid cells upon SARS-CoV-2 infection (Bedin et al., 2020) , and strongly correlates with SARS-CoV-2 RNA counts on single cell analysis of bronchoalveolar lavages from COVID-19 patients (Lempp et al., 2021) . Siglec-1 is involved in the uptake by APCs of different viruses (including HIV-1 and Ebola virus) via recognition of syalilated gangliosides anchored on the viral membranes (Bavari et al., 2002; Chan et al., 2008; Feizpour et al., 2015; Izquierdo-Useros et al., 2012a; Lorizate and Kräusslich, 2011; Panchal et al., 2003) . We therefore tested if Siglec-1 could recognize and capture SARS-CoV-2 by assessing viral uptake in two complementary cellular models. First, we used the antigen presenting Raji B cell line transfected with different lectins, whose level of expression is shown in Figure 3A) . We next tested if Siglec-1 uptake of SARS-CoV-2 relied on the recognition of sialylated ligands, which most likely are gangliosides exposed on viral membranes, as previously described for HIV-1 and Ebola virus (Izquierdo-Useros et al., 2012a , 2012b Perez-Zsolt et al., 2019; Puryear et al., 2012 Puryear et al., , 2013 . This was confirmed using a Raji cell line transfected with the Siglec-1 mutant R116A, which contains a mutation critical for sialic acid recognition (Hartnell et al., 2001; Puryear et al., 2013) that did not trap SARS-CoV-2 ( Figure 3A) , as previously shown for other viruses Africa) were equally trapped via Siglec-1 receptor, but were not captured by the mutated Siglec-1 R116A, indicating that sialic acid recognition is critical for viral trapping ( Figure 3C ).

We also used a second cellular model of monocyte-derived macrophages and DCs to verify the role of Siglec-1 receptor on primary cells. Myeloid cells previously treated or not with IFN-α were pulsed with SARS-CoV-2, washed and assayed by ELISA as described for Raji cells. Of note, all myeloid cells trapped SARS-CoV-2 but IFN-α activated APCs, which display higher amounts of Siglec-1 ( Figure 2D ), were the cells with higher uptake capacity ( Figure 3D ). To further investigate whether SARS-CoV-2 viral interaction was mediated by Siglec-1, we used the anti-Siglec-1 mAb 7-239. While isotype mAb had no inhibitory effect, pre-treatment with 7-239 blocked SARS-CoV-2 uptake ( Figure 3E ), and this Siglec-1 dependency was higher for IFN-α activated 

Siglec-1 has a dual role enhancing infectivity of various viruses, either facilitating fusion on APCs, as is the case for Ebola virus, or mediating transmission to other target cells, as is the case for retroviruses. This later mechanism is relevant when APCs are not directly susceptible to infection, as it has been reported for HIV-1 on DCs (Laguette et al., 2011) . The inefficient support of SARS-CoV-2 replication on APCs (Figure 1) would suggest that Siglec-1 could mediate SARS-CoV-2 transmission to target cells in 1 1 infection for SARS-CoV-2 bound via Siglec-1. We pulsed distinct Raji cells with equal amounts of a SARS-CoV-2 Spike pseudotyped HIV-1 construct lacking the lentiviral glycoprotein, but containing a luciferase reporter gene. Pulsed Raji cells were extensively washed and co-cultured with different target cell lines expressing either ACE2 alone or ACE2 and TMPRSS2, a protease required for priming SARS-CoV-2

Spike (Hoffmann et al., 2020) . While Raji Siglec-1 cells effectively transferred SARS-CoV-2 to both cellular targets, Raji cells transfected with DC-SIGN marginally transmitted the virus, and cells devoid of any of these two lectins did not transfer SARS-CoV-2 ( Figure 4A ). Moreover, trans-infection relied on Siglec-1 uptake of SARS-CoV-2 via recognition of sialylated ligands, as the Siglec-1 mutant R116A did not trans-infect SARS-CoV-2 ( Figure 4A ). No direct infection of Raji cells was detected, as seen when assessing pulsed cells in the absence of ACE2-expressing cellular targets. Experiments using wild-type virus confirmed these observations. Raji cells exposed to SARS-CoV-2 or left untreated for 4h were washed and co-cultured with Vero E6 cells at the indicated ratios for 48 h ( Figure 4B ). While Raji Siglec-1 induced higher cytopathic effect on Vero E6 cells, this effect was blocked by

Remdesivir treatment and not observed for those co-cultures containing Raji Siglec-1 mutant R116A ( Figure 4B ).

We also tested primary monocyte-derived myeloid cells activated with IFNα to upregulate Siglec-1 expression, and found that DCs where much more efficient at transmitting SARS-CoV-2 when compared to macrophages ( Figure 4C ). We used the α -Siglec-1 mAb 7-239 to explore whether SARS-CoV-2 trans-infection could be blocked with this antibody. While isotype mAb had no inhibitory effect, pre-treatment with 7-239 blocked SARS-CoV-2 trans-infection to target cells mediated by IFNαactivated DCs ( Figure 4D ). No direct infection of DCs was detected, as seen when assessing pulsed cells in the absence of ACE2-expressing targets. Thus, SARS-CoV-2 retention via Siglec-1 allows trans-infection of cells expressing ACE2 and TMPRSS2 receptors, especially by DCs.

We next interrogated single cell RNA sequencing data (Speranza et al., 2021) previously collected from pulmonary tissues of African Green Monkeys (AGMs) to 1 2 corroborate our prior in vitro observations (Supplementary Figure 3) . We focused on myeloid APCs and analyzed which of these populations expressed SIGLEC1 mRNA in the pulmonary tissues of AGMs infected with SARS-CoV-2 over time ( Figure 5A ). We found that tissue-resident alveolar macrophages, DCs, monocyte-derived macrophages or interstial macrophages, monocytes and pDCs all upregulated SIGLEC1 transcript expression 3 days post-infection (dpi), and that expression was still detectable at 10 dpi, mostly on both types of macrophages ( Figure 5A ). Viral RNA was highly detected at 3 dpi, but decreased at 10 dpi ( Figure 5B) , consistent with the resolution of SARS-CoV-2 infection in these NHP models with mild COVID-19. When we compared the expression of SIGLEC1 on cells with or without detectable viral RNA, we found that all cells induced SIGLEC1 transcription upon SARS-CoV-2 infection, although this was significantly more abundant only on alveolar macrophages or interstitial macrophages containing viral RNA, followed by monocytes and DCs, where differences did not reach statistical significance ( Figure 5C ). Indeed, a significant positive correlation between SARS-CoV-2 and SIGLEC1 transcripts was detected for all APCs but pDCs. Moreover, immunohistochemistry analysis of the pulmonary tissue of a SARS-CoV-2 infected rhesus macaque from a previous study (Hoang et al., 2021) collected at 10 dpi, confirmed at the protein level the co-expression of Siglec-1 and SARS-CoV-2 nucleocapsid in cells with a typical myeloid cell morphology ( Figure 5D ).

Finally, we addressed which APCs better sensed SARS-CoV-2 to produce cytokines and IFN-related molecules during the course of the infection in AGMs with mild COVID-19 disease progression ( Figure 6A ). IL-6 and IFN-γ transcripts were significantly triggered by viral presence at 3 dpi in alveolar macrophages or interstitial macrophages and to lesser extend in monocytes and pDCs, but never in DCs ( Figure   6A ). For IP-10 (CXCL10), however, the induction was also detected for DCs ( Figure   6A ), as we had previously observed by Luminex immunocapture in human cells. For

IFN-2α was mostly detected at 3 dpi in interstitial macrophages, monocytes and pDCs not expressing viral RNA ( Figure 6A ). Same trends were observed for all aforementioned molecules in APCs expressing SIGLEC1 transcripts ( Figure 6B ). When we interrogated GO processes differentially regulated on macrophages containing SARS-CoV-2 RNA, we found that these cells actively modified several processes related to negative regulation of interferon production or regulation of cytokine 1 4

Here we identified a role for Siglec-1 in SARS-CoV-2 recognition. This IFN-inducible receptor is increased on activated human myeloid cells, and is also detected bearing viruses on APCs of pulmonary tissues of SARS-CoV-2-infected NHP. The association between Siglec-1 expressing APCs and SARS-CoV-2 was also found in peripheral blood monocytes and in the pulmonary lavages of SARS-CoV-2 infected individuals (Bedin et al., 2020; Lempp et al., 2021) . In the present study, we define how this interaction takes place via recognition of syalilated gangliosides detected on the viral membrane of SARS-CoV-2 particles. The capacity of Siglec-1 to bind different SARS-CoV-2 variants is consistent with a Spike-independent mode of viral recognition.

Myeloid APCs trapped and engulfed large amounts of SARS-CoV-2 via Siglec-1.

Viruses were retained within Sigelc-1 positive VCCs that resemble to those previously NHP. Yet, both activated and steady state APCs were able to continuously process captured viruses in the absence of detectable viral replication. Macrophages secreted higher amounts of cytokines upon viral capture as compared to DCs, indicating that the hyperactivation of these APCs could drive the exacerbated inflammatory cytokine storm-like condition associated with ARDS. These cytokines include IL-6 and TNF-α, which are significant predictors of disease severity and death (Valle, 2020) , and MIP1α , which is elevated in the plasma of intensive care unit patients (Huang et al., 2020) .

However, in the non-severe SARS-CoV-2 infection NHP model, we failed to detect TNF-α nor MIP1-α transcripts at 3 dpi, but IL-6 expression followed the same pattern as that detected in vitro on human cells, and was mostly restricted to macrophages. IP-10, an IFN-stimulated gene which is normally up-regulated along Siglec-1 (Rose et al., 2013) , is also increased in patients with unfavorable COVID-19 outcomes (Yale Finally, these studies could pave the way to understand if Siglec-1 modulation with mAbs could decrease cytokine storm implicated in ARDS associated to severe COVID-19, as recently suggested for other lectin receptors (Lu et al., 2021) . Since the capture of very distant viruses such as HIV-1, Ebola virus and now SARS-CoV-2 is regulated by Siglec-1, strategies targeting this receptor may offer new broad-spectrum inhibitors for enveloped viruses, which may be even effective for future outbreaks. Virus Isolation, Titration and Sequencing. Unless otherwise specified, SARS-CoV-2 used was the virus isolated in March 2020 from a nasopharyngeal swab as described in (Rodon, 2021 

vector was generated with the Geneart service (Thermofisher Scientific). Coding sequence included the first 615 amino acids from the Human ACE2 sequence, with H345A and H505A mutations to inactivate the catalytical sites, followed by the constant region of the heavy chain of the murine IgG1. For protein production, Expi293F cells (Thermofisher Scientific) were transfected with ACE2-mFc vector at a density of 2.5 x 10 6 cells/mL using Expifectamine (Thermofisher Scientific 

were performed pulsing 0.5 x 10 6 Raji or 1 x 10 6 myeloid cells at a rate of 70 ng of Nucleocapsid at 37ºC for the indicated timepoints. For blockade, cells were preincubated for 15 min at RT with 10 μ g/mL of mAbs α -Siglec-1 7-239, or IgG1 isotype control (BD Biosciences), or left untreated before viral exposure. After extensive washing, cells were lysed at a constant concentration of 1x10 6 cells/mL, centrifuged to remove cellular debris and assayed with a SARS-CoV-2 Nucleocapsid protein (NP)

High-sensitivity Quantitative ELISA (ImmunoDiagnostics). For degradation experiments, myeloid cells were exposed to SARS-CoV-2 for 4h, extensively washed, and left in culture for the indicated timepoints until cell associated viral content and viral release to the supernatant were measured with the indicated ELISA kit.

activated with LPS) were exposed to SARS-CoV-2 with an MOI of 1 for 24h, fixed with paraformaldehyde (PFA) at 4% (Biotium) and glutaraldehyde 1% (Sigma Aldrich/Merck) for one hour at room temperature (RT) and processed for embedding in resin, ultramicrotomy and transmission electron microscopy as previously described (Tenorio et al., 2018) . Briefly, after fixation the samples were washed three times with PBS and cells were gently scraped with a rubber policeman. Cell pellets were postfixed with 1% osmium tetroxide + 0.8% potassium ferrocyanide in water for 1h on ice. The samples were dehydrated on ice with a gradual series of acetone and infiltrated at RT with epoxy resin. After heat polymerization the samples were sectioned with a UC6 microtome with a nominal feed of 70 nm. Sections were collected on 300 mesh bare copper grids and contrasted with 4% aqueous uranyl acetate, followed by Reynold´s lead citrate. Images were taken either using a Jeol 1011 run at 100 kV equipped with a Gatan ES1000W camera or a Jeol 1400 run at 80kV with a Gatan Oneview camera. SARS-CoV-2 particles, a fixation that does not alter quantification (Dowall et al., 2009 ). Before plate acquisition PFA was washed and changed for sheath fluid. CoV-2 (MOI=0.01) and representative Siglec-1 surface staining of myeloid cells equally activated and also exposed to LPS analyzed by FACS. Results from six independent biological replicates and two experiments. Super resolution microscopy of SARS-CoV-2. Top images: viruses stained with antinucleocapsid Abs (red) and ACE2-mFc fusion protein that interacts with the Spike of SARS-CoV-2 (green). Bottom images: viruses stained with anti-GM1 Abs (red) and

ACE2-mFc fusion protein that interacts with the Spike of SARS-CoV-2 (green).

Percentage of co-staining for each is shown. Scale bar: 100 nm. Virus irradiated 3 dpi SARS−CoV−2 3 dpi SARS−CoV−2 10 dpi

Mediate Cellular Entry by Ebola Virus in cis and in trans

Lower Respiratory Tract Myeloid Cells Harbor SARS-Cov-2 and Display an Inflammatory Phenotype

Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses

Monocyte CD169 expression as a biomarker in the early diagnosis of COVID-19 (Infectious Diseases

Severe Covid-19

Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells

The Epidemiological Characteristics of an Outbreak of

Novel Coronavirus Diseases (COVID-19) -China

Retroviruses human immunodeficiency virus and murine leukemia virus are enriched in phosphoinositides

SARS-CoV-2 evades immune detection in alveolar macrophages

Multiplex cytokine profiling with highly pathogenic material: Use of formalin solution in luminex analysis

Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK-ninth update

Quantifying lipid contents in enveloped virus particles with plasmonic nanoparticles

Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses

Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection

Severe COVID-19 Is Fueled by Disrupted Gut Barrier Integrity

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations

Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Dynamic Imaging of Cell-Free and Cell-Associated Viral Capture in Mature Dendritic Cells

Siglec-1 Is a Novel Dendritic Cell Receptor That Mediates HIV-1 Trans-Infection Through Recognition of Viral Membrane Gangliosides

The lipidomes of vesicular stomatitis virus, semliki forest virus, and the host plasma membrane analyzed by quantitative shotgun mass spectrometry

SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx

Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing activity of different classes of antibodies

Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR

Role of Lipids in Virus Replication

SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety 3 2 family member 2

Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses

Identification of Siglec-1 null individuals infected with HIV-1

COVID-19: consider cytokine storm syndromes and immunosuppression

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding

Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry

HIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells

HIV-1 incorporation of host-cell-derived glycosphingolipid GM3 allows for capture by mature dendritic cells

Interferon-inducible mechanism of dendritic cell-mediated HIV-1 dissemination is dependent on Siglec-1/CD169

Search for SARS-CoV-2 inhibitors in currently approved drugs to tackle COVID-19 pandemia (Microbiology)

IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus

Adaptive immunity to SARS-CoV-2 and COVID-19

Viruses exploit the tissue physiology of the host to spread in vivo

DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells

Single-cell RNA sequencing reveals SARS-CoV-2 infection dynamics in lungs of African green monkeys

Reovirus σ NS and µNS Proteins Remodel the Endoplasmic Reticulum to Build Replication Neo-Organelles. 9

DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist

SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity

Middle East respiratory syndrome coronavirus shows poor replication but significant induction of antiviral responses in human monocyte-derived macrophages and dendritic cells

Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey

An inflammatory cytokine signature predicts COVID-19 severity and survival

Sex differences in immune responses that underlie COVID-19 disease outcomes

Longitudinal analyses reveal immunological misfiring in severe COVID-19

SARS-coronavirus replication in human peripheral monocytes/macrophages

HIV traffics through a specialized, surface-accessible intracellular compartment during trans-infection of T cells by mature dendritic cells

We acknowledge J. Pedroza from the CMCIB for his constant help at the BSL3 facility.We thank C. Esteban from the microbiology department for identifying two different variants used in this study. We also thank M. Parera from IrsiCaixa for her outstanding help in sequencing viral variants. We are grateful to M. Fernandez of the IGTP Cytometry platform for his excellent assistance for Luminex acquisition and analysis, and to E. Rebollo from the Advanced Fluorescence Microscopy Unit IBMB-PCB. We would like to thank Advanced Light Microscopy Unit at the Centre for Genomic Regulation (CRG), Barcelona, Spain for the access to Leica STED microscope.

The research of CBIG consortium (constituted by IRTA-CReSA, BSC, & IrsiCaixa) is supported by Grifols pharmaceutical. The authors also acknowledge the crowdfunding initiative #Yomecorono (https://www.yomecorono.com). J.M-P. is supported by grant PID2019-109870RB-I00 from the Spanish Ministry of Science and Innovation and in part also by Grifols. CR lab is funded by RTI2018-094445-B100 (MCIU/AEI/FEDER, UE). The authors also acknowledge the crowdfunding initiative #Yomecorono William and Lula Pitts Foundation (to MPa). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

3 5